Zenas BioPharma (NASDAQ:ZBIO) Stock Jumps 6.9% – Should You Buy?

Zenas BioPharma, Inc. (NASDAQ:ZBIO)’s share price traded up 6.9% during mid-day trading on Monday. The stock traded as high as $26.67 and last traded at $26.5490. 59,467 shares traded hands during trading, a decline of 93% from the average session volume of 805,896 shares. The stock had previously closed at $24.84.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ZBIO shares. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th. Morgan Stanley increased their price target on shares of Zenas BioPharma from $22.00 to $32.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Zenas BioPharma in a report on Tuesday, October 6th. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, Wedbush restated an “outperform” rating and set a $45.00 price target on shares of Zenas BioPharma in a research report on Wednesday, September 30th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Zenas BioPharma Stock Up 8.6%

The company has a market capitalization of $1.76 billion, a PE ratio of -3.00 and a beta of -0.90. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93. The business’s 50 day simple moving average is $30.16 and its 200 day simple moving average is $25.50.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Thursday, August 13th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The business had revenue of $1.00 million during the quarter, compared to the consensus estimate of $15.00 million. As a group, analysts anticipate that Zenas BioPharma, Inc. will post -5.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors have recently modified their holdings of ZBIO. Quantbot Technologies LP purchased a new stake in Zenas BioPharma during the second quarter worth about $49,000. Jupiter Topco LLC purchased a new stake in Zenas BioPharma during the second quarter worth approximately $201,000. The Manufacturers Life Insurance Company acquired a new position in Zenas BioPharma in the second quarter valued at $204,000. Sei Investments Co. purchased a new position in Zenas BioPharma during the 1st quarter worth approximately $242,000. Finally, Engineers Gate Manager LP purchased a new position in shares of Zenas BioPharma during the second quarter worth approximately $329,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and Fc?RIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.